BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Song Z, Ma Y, Jiang D, Zhao R, Dong F. Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series. Front Med (Lausanne) 2022;9:890339. [PMID: 35712098 DOI: 10.3389/fmed.2022.890339] [Reference Citation Analysis]
2 Cooper J, Kotha S, Sticova E, Georgiou A. Managing Immune checkpoint inhibitor induced hepatitis in a patient with concurrent hepatitis C. Current Problems in Cancer: Case Reports 2021;3:100066. [DOI: 10.1016/j.cpccr.2021.100066] [Reference Citation Analysis]
3 Ferrando-Martinez S, Snell Bennett A, Lino E, Gehring AJ, Feld J, Janssen HLA, Robbins SH. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. Front Immunol 2021;12:648420. [PMID: 34589081 DOI: 10.3389/fimmu.2021.648420] [Reference Citation Analysis]
4 Ziogas DC, Gogas H. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al. J Immunother Cancer 2021;9:e002391. [PMID: 33737346 DOI: 10.1136/jitc-2021-002391] [Reference Citation Analysis]
5 Zhong L, Zhong P, Liu H, Li Z, Nie Q, Peng W. Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies: Real-world evidence from a retrospective study using propensity score matching. Medicine (Baltimore) 2021;100:e28113. [PMID: 34889269 DOI: 10.1097/MD.0000000000028113] [Reference Citation Analysis]
6 Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [DOI: 10.4254/wjh.v14.i3.525] [Reference Citation Analysis]
7 Wang K, Xia Y, Zhu Y, Yu W, Guo Y, Liu L. Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. J Immunother Cancer 2021;9:e003195. [DOI: 10.1136/jitc-2021-003195] [Reference Citation Analysis]
8 Switzer B, Haanen J, Lorigan PC, Puzanov I, Turajlic S. Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002835. [PMID: 34272309 DOI: 10.1136/jitc-2021-002835] [Reference Citation Analysis]
9 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lasagna A, Zuccaro V, Sacchi P, Chiellino S, Bruno R, Pedrazzoli P. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future Oncol 2021;17:1577-80. [PMID: 33590770 DOI: 10.2217/fon-2020-1196] [Reference Citation Analysis]
11 Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 2020;8:e001322. [PMID: 33144335 DOI: 10.1136/jitc-2020-001322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Yang K, Han L, Wu S, Qu X, Li Q, Zhao C, Zhou J, Jin X, Wang Y, Yan D, Cheng Z, Hua Y, Zhang Y, Ge Y, Sun J, Deng W, Zhao L, Zhao Y. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunol Immunother 2021. [PMID: 34689233 DOI: 10.1007/s00262-021-03083-3] [Reference Citation Analysis]
13 Wang T, Yeh MM, Avigan MI, Pelosof L, Feldman GM. Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). AAPS J 2021;23:99. [PMID: 34401948 DOI: 10.1208/s12248-021-00629-2] [Reference Citation Analysis]